What are the indications for ribociclib in the adjuvant and metastatic settings of hormone receptor‑positive, HER2‑negative breast cancer?

Indications of Ribociclib in Breast Cancer

Ribociclib is FDA-approved for two distinct settings in HR-positive, HER2-negative breast cancer: (1) adjuvant treatment of stage II-III early breast cancer at high risk of recurrence in combination with an aromatase inhibitor, and (2) treatment of advanced/metastatic disease in combination with either an aromatase inhibitor or fulvestrant. 1

Adjuvant Setting (Early Breast Cancer)

FDA-Approved Indication

Ribociclib is indicated in combination with a nonsteroidal aromatase inhibitor (NSAI) for adjuvant treatment of adults with HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence 1. This approval was granted in September 2024 based on the NATALEE trial 2.

Specific Eligibility Criteria

The NATALEE trial enrolled patients with:

• Stage IIA disease (T2N0) requiring at least one of: grade 2 disease with Ki-67 ≥20%, high genomic risk, or grade 3 disease
• Stage IIB or III disease (any grade)
• Both premenopausal and postmenopausal women, as well as men 3, 4

Dosing and Duration

• Ribociclib 400 mg once daily (3 weeks on, 1 week off) for 3 years
• Combined with letrozole 2.5 mg or anastrozole 1 mg daily for ≥5 years
• Premenopausal women and men also receive goserelin every 28 days 3, 4

Efficacy Data

At the final invasive disease-free survival (iDFS) analysis with 33.3 months median follow-up:

• 3-year iDFS: 90.7% with ribociclib + NSAI vs 87.6% with NSAI alone
• Hazard ratio 0.75 (95% CI 0.63-0.89, P=0.0012)
• Absolute benefit of 3.1% at 3 years 5

The benefit was consistent across key subgroups including node-negative and node-positive disease 5.

ASCO Guideline Recommendation

The 2024 ASCO guideline does NOT currently recommend routine use of ribociclib in the adjuvant setting 3. The guideline states that while NATALEE showed statistically significant iDFS improvement, the Panel promotes use of abemaciclib primarily in those who would have been eligible for monarchE based on that trial's eligibility criteria. This reflects the timing of guideline publication (before FDA approval of ribociclib) and the Panel's preference for the more mature abemaciclib data.

Key Safety Considerations in Adjuvant Setting

• Grade ≥3 adverse events: 64% with ribociclib vs 19% with NSAI alone
• Grade 3-4 neutropenia: 43.8% (most common)
• Liver-related adverse events grade ≥3: 8.3% (most frequent cause of discontinuation at 8.9%)
• QT prolongation (any grade): 5.2% 3

Metastatic/Advanced Setting

FDA-Approved Indications

Ribociclib is approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with 1:

1. An aromatase inhibitor as initial endocrine-based therapy
2. Fulvestrant as initial endocrine-based therapy OR following disease progression on endocrine therapy

This applies to postmenopausal women, premenopausal women (with ovarian suppression), and men 1, 6.

Dosing in Metastatic Setting

Ribociclib 600 mg once daily (3 weeks on, 1 week off) until disease progression or unacceptable toxicity 1

First-Line with Aromatase Inhibitor

MONALEESA-2 (Postmenopausal Women)

• Ribociclib + letrozole vs placebo + letrozole
• Demonstrated significant PFS and OS benefit 1

MONALEESA-7 (Pre/Perimenopausal Women)

For the NSAI subgroup (ribociclib + NSAI + goserelin):

• Median PFS: 27.5 months vs 13.8 months (HR 0.569)
• Overall survival: HR 0.699 (95% CI 0.501-0.976)
• Overall response rate: 50.5% vs 36.2% 1

COMPLEEMENT-1 (Men)

• 39 male patients treated with ribociclib + letrozole + goserelin/leuprolide
• Overall response rate: 46.9% (95% CI 29.1-65.3), consistent with female patients 6

With Fulvestrant (First or Second-Line)

MONALEESA-3

Enrolled postmenopausal women with no prior or one prior line of endocrine therapy for advanced disease:

• Median PFS: 20.5 months vs 12.8 months (HR 0.593, P<0.0001)
• Overall survival: HR 0.724 (95% CI 0.568-0.924, P=0.00455)
• 42-month OS: 57.8% vs 45.9% (28% reduction in risk of death)
• Overall response rate: 40.9% vs 28.7% 7, 1

ASCO Guideline Recommendation for Metastatic Disease

The 2021 ASCO guideline strongly supports CDK4/6 inhibitors (including ribociclib) with endocrine therapy as preferred first-line treatment for HR-positive, HER2-negative metastatic breast cancer 7. The survival benefits with ribociclib are described as "impressive" and have "solidified the role of these targeted agents."

Clinical Interpretation for Metastatic Setting

Ribociclib combinations are optimal for:

• First-line treatment (preferred approach for majority of patients)
• Patients intolerant to aromatase inhibitors (use fulvestrant combination)
• Those with recurrence within 1 year of adjuvant AI therapy (use fulvestrant combination)
• Those for whom single-agent endocrine therapy was preferred first-line (can use fulvestrant combination in second-line) 7

Key Safety Considerations in Metastatic Setting

From MONALEESA-3:

• Grade 3-4 neutropenia: 46.6% (ribociclib) vs 0% (placebo)
• Grade 3-4 leukopenia: 13.5% vs 0%
• Liver-related adverse events grade ≥3: common cause of discontinuation
• QT prolongation: requires monitoring 7, 1

Special Populations

Older Patients (≥70 years)

The RibOB study demonstrated efficacy in patients ≥70 years (median age 76,30% ≥80 years):

• Median PFS: 36 months
• Efficacy similar regardless of frailty status (G8 score)
• However, 57% required dose reduction to 400 mg and 23% to 200 mg
• Only 20% continued full 600 mg dose
• 43% discontinued before progression 8

This suggests starting dose may need individualization in older/frailer patients, though the standard FDA-approved dose remains 600 mg in metastatic and 400 mg in adjuvant settings.

Critical Monitoring Requirements

Mandatory Monitoring

• Neutrophil counts: Before starting, every 2 weeks for first 2 cycles, then monthly
• Liver function tests: Before starting, every 2 weeks for first 2 cycles, then monthly
• ECG and electrolytes: Baseline, Day 14 of first cycle, beginning of cycle 2, then as clinically indicated
• QTcF prolongation monitoring: Especially important given 5.2% incidence 3, 1

Contraindications and Cautions

Ribociclib should be avoided or used with extreme caution in:

• Patients with baseline QTc prolongation
• Those on medications that prolong QT interval
• Patients with significant cardiac morbidities
• Those with baseline liver dysfunction 9

In such cases, alternative CDK4/6 inhibitors (palbociclib or abemaciclib) may be preferred 9.